Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01166737
Other study ID # AGO-OVAR OP.4 DESKTOP III
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2010
Est. completion date December 31, 2020

Study information

Verified date December 2021
Source AGO Study Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this third DESKTOP study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.


Description:

A predictive score identifying patients who might achieve a complete resection is deemed necessary to select the right patients for a prospective trial on cytoreductive surgery in relapsed ovarian cancer. Study centres are selected due to their surgical experience in ovarian cancer and/or participation in prior surgical trials in this field. Patients who matched eligibility criteria were allocated randomly 1:1 prospectively to cytoreductive surgery followed by platinum based combination chemotherapy or to platinum based combination chemotherapy alone .


Recruitment information / eligibility

Status Completed
Enrollment 408
Est. completion date December 31, 2020
Est. primary completion date January 17, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria: - Patients with first recurrence of platinum sensitive, invasive epithelial ovarian-, fallopian tube- or primary peritoneal cancer of any initial stage. - Progression-free interval of at least 6 months after end of last platinum-containing therapy, or recurrence within 6 months or later after primary surgery if the patient has not received prior chemotherapy in patients with FIGO I. Non cytostatic maintenance therapy not containing platinum will not be considered for this calculation. - A positive AGO-score. Obligatory requirements for a positive AGO recurrence score in platinum-sensitive disease: 1. Performance status ECOG 0 2. No residual tumor after primary surgery (if unknown, alternatively primary FIGO stage I/II). If report from 1st surgery is not available contact study chairman who will decide whether inclusion is possible or not. 3. Absence of ascites (cut off < 500 ml: radiological or ultrasound estimation) - Complete resection of the tumor by median laparotomy seems possible - Patients who have given their signed and written informed consent and their consent to data transmission and -processing. Exclusion Criteria: - Patients with non-epithelial tumors as well as borderline tumors. - Patients without recurrence who are scheduled for diagnostic/second-look surgery or debulking surgery after completion of chemotherapy - More than one prior chemotherapy - Patients with second, third, or later recurrence - Patients with second malignancies who have been treated by laparotomy, as well as other neoplasms, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected. - Patients with so-called platinum-refractory tumor, i.e. progression during chemotherapy or recurrence within 6 months after end of former first platinum-containing therapy - Only palliative surgery planned - Radiological signs suggesting metastases not accessible to surgical removal (i.e. complete resection is deemed impossible) - Any concomitant disease not allowing surgery and/or chemotherapy - Any medical history indicating excessive peri-operative risk - Any current medication inducing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents, bevacizumab)

Study Design


Intervention

Procedure:
Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection

Locations

Country Name City State
Austria Medizinische Universität Graz, Universitätsklinik für Frauenheilkunde Graz, Abteilung Gynäkologie u. Geburtshilfe Graz
Austria Universitätsklinikum Innsbruck, Univ. Klinik für Gynäkologie und Geburtshilfe Innsbruck
Austria Medizinische Universität Wien,Universitätsklinik für Frauenheilkunde Wien
Austria Wilhelminenspital der Stadt Wien, Gynäkologisch und Geburtshilfliche Abteilung Wien
Belgium UZ Leuven Leuven
China Zhejiang Cancer Hospital, Gynecology Oncology Hangzhou
China Fudan University Cancer Hospital, Gynecologic Oncology Shanghai
China Fudan University Zhongshan Hospital, Obstetrics and Gynecology Shanghai
China Suzhou Municipal Hospital, Gynecologic and Obstetrics Suzhou
Denmark Aalborg Hospital Aalborg
Denmark Aarhus University Hospital,Oncology Aarhus
Denmark Ringshospitalet Copenhagen University Hospital; Oncology Copenhagen
Denmark Herlev Hospital Herlev
Denmark Odense University Hospital, Gynaecology and Obstetrics Odense
France Institut Bergonié, Gynecology Bordeaux
France Centre Francois Baclesse Caen
France Centre Jean Perrin Clermont-Ferrand
France Centre Antoine Lacassagne Nice
France Hôpital Européen Georges Pompidou Paris
France Hôpital Tenon Paris
France Insitut Jean Godinot, Service Rubis - Oncologie Médicale Reims
France Centre Eugène Marquis Rennes
France Centre Henri Becquerel Rouen
France Centre Hospitalier Universitaire Charles-Nicolle Rouen
France Centre René Gauducheau Saint-Herblain
France Centre Claudius Regaud Toulouse
Germany Hochtaunus-Kliniken gGmbH, Frauenklinik Bad Homburg
Germany Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde Berlin
Germany Universitätsklinikum Carl Gustav Carus, Klinik für Frauenheilkunde u. Geburtshilfe Dresden
Germany Evangelisches Krankenhaus, Frauenklinik Düsseldorf
Germany Kaiserswerther-Diakonie, Florence-Nightingale Krankenhaus, Gynäkologie Düsseldorf
Germany Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Gynäkologische Onkologie Essen
Germany Klinikum der JWG Universität Frankfurt, Klinik für Gynäkologie und Geburtshilfe Frankfurt am Main
Germany Universitätsklinikum Freiburg, Frauenklinik Freiburg
Germany Klinikum Fürth, Frauenklinik Nathanstift Fürth
Germany Georg-August-Universität Göttingen, Universitäts-Frauenklinik Göttingen
Germany Gynecologic Clinic of the Ernst-Moritz-Arndt-University Greifswald
Germany Medizinische Hochschule, Klinik für Frauenheilkunde u. Geburtshilfe Hannover
Germany Klinikum Kempten, Klinik für Frauenheilkunde und Geburtshilfe Kempten
Germany Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe Kiel
Germany Klinikum Konstanz, Frauenklinik Konstanz
Germany Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe Lübeck
Germany Universitätsklinikum Mainz, Frauenklinik Mainz
Germany Klinikum der Universität München-Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe München
Germany Klinikum Dritter Orden, Gynäkologie und Geburtshilfe München
Germany Oberschwaben Klinik, Krankenhaus St. Elisabeth, Frauenklinik Ravensburg
Germany Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde und Geburtshilfe d. Universität Regensburg Regensburg
Germany Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH, Frauenklinik Schweinfurt
Germany Universitätsklinikum, Universitätsfrauenklinik Ulm
Germany Ammerland-Klinik GmbH, Frauenklinik Westerstede
Germany HSK, Dr. Horst Schmidt Klinik GmbH, Klinik für Gynäkologie u. Gynäkologische Onkologie Wiesbaden
Italy Centro di Riferimento Oncologico,Struttura Operativa complessa Chirurgia Oncologica Ginecologica Aviano
Italy Fondazione IRCCS Istituto Nazionale Tumori di Milano Milan
Italy Istituto Europeo di Oncologia, Divisione di Ginecologia Milan
Italy Istituto Nazionale Tumori di Napoli, Gynecologic Oncology Naples
Korea, Republic of Seoul National University Hospital, Department of Obstetrics and Gynecology Seoul
Norway Norwegian Radium Hospital, Oslo University Hospital, Gynecologic Oncology Oslo
Spain ICO Badalona - H. U. Germans Trias i Pujol Badalona
Spain Hospital Clinic Barcelona, Oncology Barcelona
Spain Hospital de la Santa Creu i Sant Pau, Oncology Barcelona
Spain ICO-Hospital Universitari de Girona Dr. Josep Trueta, Servicio de Oncologia de Girona Girona
Spain Avinguda Granvia de l'Hospitalet de Llobregat, Hospital de Bellvitge, Gynaecology Hospitalet de Llobregat
Spain Hospital Son Llàtzer, Oncology Palma de Mallorca
Spain Hospital de Navarra, Oncology Pamplona
Spain Fundación Instituto Valenciano de Oncologia Valencia
Spain Hospital Universitari i Politècnic la Fe, Oncology Valencia
Sweden Linköping University Hospital, Department of Obstetrics and Gynecology Linköping
Sweden Karolinska University Hospital, Oncology Stockholm
United Kingdom Birmingham City Hospital, Cancer Research Team Birmingham
United Kingdom Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Gynaecological Oncology Cambridge
United Kingdom Queen Elizabeth Hospital Gateshead, Northern gynaecological oncology centre Gateshead
United Kingdom Royal Surrey Country Hospital,St Lukes Cancer Centre Guildford
United Kingdom Lincoln County Hospital, Oncology Lincoln
United Kingdom Imperial College Healthcare NHS Trust Hammersmith Hospital, Medical Oncology London
United Kingdom Royal Marsden NHS Foundation Trust, Gynae research, Mulberry House London
United Kingdom St Bartholomew´s Hospital and Queen´s Hospital,Gynaecological Cancer Centre London
United Kingdom University College London Hospital, Cancer clinical trails unit London
United Kingdom Central Manchester Foundation NHS Trust, St Mary´s Hospital, Gynaecology Manchester
United Kingdom Queen Elizabeth the Queen Mother Hospital,East Kent Gynaeoncology Centre Margate
United Kingdom Northampton General Hospital, Gynaecological Oncology Northampton
United Kingdom East and North Hertfordhire NHS Trust,Mount Vernon Hospital,Medical Oncology Northwood
United Kingdom Norfolk & Norwich University Hospital,Obstetrics & Gynaecology Norwich
United Kingdom Nottingham University Hospital, City Campus, Oncology Nottingham
United Kingdom Royal Hallamshire Hospital & Weston Park Hospital, Cancer Clinical Trials Centre Sheffield
United Kingdom Princess Anne Hospital, gynaecology Southampton
United Kingdom New Cross Hospital,Oncology/Gynaecology Wolverhampton

Sponsors (5)

Lead Sponsor Collaborator
AGO Study Group ARCAGY/ GINECO GROUP, Cancer Research UK, Grupo Español de Investigación en Cáncer de Ovario, Shanghai Gynecologic Oncology Group

Countries where clinical trial is conducted

Austria,  Belgium,  China,  Denmark,  France,  Germany,  Italy,  Korea, Republic of,  Norway,  Spain,  Sweden,  United Kingdom, 

References & Publications (1)

Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score Approximately 36 months after last patient randomized and observation of 244 events
Secondary Progression free survival patients with platinum-sensitive recurrent ovarian cancer with a positive AGO Score Progression free survival is defined as interval between date of randomization and 2nd relapse/progression or death (whatever occurs first).
Secondary Quality of Life measures with EORTC QLQ-C30 Global Health Status (GHS) GHS scale-core item 29, 30; ranges 0-100 Baseline, 6, and 12 months after randomization
Secondary Quality of Life measures with EORTC QLQ-C30 Symptom Scale Insomnia Item 11, ranges 0-100 Baseline, 6, and 12 months after randomization
Secondary Quality of Life measures with EORTC QLQ-C30 Symptom Scale Constipation Item 16, ranges 0-100 Baseline, 6, and 12 months after randomization
Secondary Quality of Life measures with FACT-G total score Composite of 27 items regarding physical, functional, social/family and emotional well-being. from 0-108 Baseline, 6, and 12 months after randomization
Secondary Quality of Life measures with FACT-O Ovarian Cancer subscale Composite of 11 items regarding specific to Ovarian Cancer patients, ranges 0-44 Baseline, 6, and 12 months after randomization
Secondary Quality of Life measures with FACT-O total score Sum of FACT-G and and Ovarian Cancer subscale, ranges 0-152 Baseline, 6, and 12 months after randomization
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2